|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A population study to define the incidence and survival of multiple myeloma in a national health service region in UK显示文摘 | Phekoo K J Schey SA Richards MA | 2004 | Br J Haematol2004，127，2： | 1 |
| 2 | A population study to define the incidence and survial of multiple myeloma in a National Health Service Region in UK显示文摘 | Schey SA Richards MA | 2004 | Br J Haematol2004，127，3： | 1 |
| 3 | Lenalidomide ( Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients 显示文摘 | Morgan GJ Schey SA Wu P | 2007 | Br J Haematol2007，137，3： | 1 |
| 4 | A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK 显示文摘 | Phekoo K J Schey SA Richards MA | 2004 | Br J Haematal2004，127，3： | 1 |
| 5 | The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma显示文摘 | Kazmi MA Ahsan G Schey SA | 2001 | Clin Lab Haematol2001，23，2： | 1 |
| 6 | Phase I study of an im- munomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma显示文摘 | Schey SA Fields P Bartlett JB | 2004 | J Clin Oncol2004，22，16： | 1 |
| 7 | Consultant haematologists,South Thames Haematology Specialist Committee:a population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK显示文摘 | Phekoo KJ Schey SA Richards MA | 2004 | Br J Haematol2004，127，3： | 1 |
| 8 | Lenalidomide(Revlimid),in combi-nation with cyclophosphamide and dexamethasone(RCD),is an effec-tive and tolerated regimen for myeloma patients显示文摘 | Morgan GJ Schey SA Wu P | 2007 | Br J Haematol2007，137，3： | 1 |
| 9 | Phase I Study of an Immunomodulatory Thalidomide Analog,CC-4047,in Relapsed or Refractory Multiple Myeloma显示文摘 | Schey SA Fields P Bartlett JB | 2004 | J Clin Oncol2004，，： | 1 |
| 10 | A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK显示文摘 | Phekoo KJ Schey SA Richards MA | | 0，，03： | 1 |
| 11 | Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma显示文摘 | Schey SA Fields P Bartlett JB | 2004 | J Clin Oncol2004，22，： | 1 |
| 12 | Phase I study of an immunomodulatory thalidomide analog,CC-4047,in relapsed or refractory multiple myeloma显示文摘 | SCHEY SA FIELDS P BARTLETT JB | 2004 | J Clin Oncol2004，22，16： | 1 |
| 13 | An UK myeloma forum phase Ⅱ study of thalidomide;long term follow-up and recommendations for treatment显示文摘 | Schey SA Cavenagh J Johnson R | 2003 | Leuk Res2003，27，10： | 1 |
| 14 | The addition of cyclo- phosphamide to lenalidomide and dexamethasone in multiply relapsed - refractory myeloma patients; a phase I / II study显示文摘 | Schey SA Morgan GJ Ramasamy K | 2010 | Br J Haema- tol2010，150，： | 1 |
| 15 | Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients显示文摘 | Nowell SA Ahn J Rae JM Scheys JO Trovato A Sweeney C | 2005 | Breast Cancer Res Treat2005，91，3： | 1 |
| 16 | Phase Ⅰ study of an immunomodulatory thalidomide analog,CC-4047,in relapsed or refractory multiple myeloma显示文摘 | SCHEY SA FIELDS P BARTLETT JB | 2004 | J Clin Oncol2004，22，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员